glp-1 gip therapy alternatives after discontinuation Many adults stop within a year with low restart rates, analysis finds Nutritional priorities to support GLP-1
Description
Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years after participants started taking the once-weekly injected medication
The GLP-1 receptor agonist market is experiencing significant growth, driven by the increasing prevalence of type 2 diabetes and obesity, and the high...
The FDA has also warned about risks during surgery because the drug slows digestion
Rationale Obesity remains a major global health challenge, severely affecting metabolic and cardiovascular health
Maintain energy levels and support metabolic processes, contributing to an active and balanced lifestyle
